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incidence
The incidence of malignant glioma is 5–7/100 000. Malignant
glioma may develop at all ages, the peak incidence being in the
fifth and sixth decades of life.
diagnosis
Malignant glioma comprises glioblastoma [World Health
Organization (WHO) grade IV], anaplastic astrocytoma (WHO
grade III), mixed anaplastic oligoastrocytoma (WHO grade III)
and anaplastic oligodendroglioma (WHO grade III). Diagnosis
after biopsy or tumor resection is made according to the revised
WHO classification.
staging and risk assessment
Staging includes imaging of the brain, ideally with magnetic
resonance imaging (MRI). If repeat imaging is deemed
necessary to determine residual disease, it should be carried out
within 24–48 h after surgery. Lumbar puncture is generally not
necessary, with the exception of adult patients with
medulloblastoma (in whom it should be carried out 3 weeks
after surgery) and staging of other organs is not needed.
Other than lower tumor grade, good performance status
and an intact neurological function, tumor resection and age
<50 years have been identified as more favorable prognostic
factors.
Prognosis depends on tumor grade and histology.
Glioblastoma carries the worst prognosis, while pure
oligodendroglioma tends to have a better outcome and
improved response to therapy. Prognosis of mixed anaplastic
oligoastrocytoma and anaplastic astrocytoma is
intermediate between glioblastoma and pure anaplastic
oligodendroglioma.
treatment plan
Patients should be evaluated by a specialized multidisciplinary
team. Special consideration needs to be given to performance
status and neurological function.
newly diagnosed patients
Surgery is commonly the initial therapeutic approach for
debulking and obtaining tissue for diagnosis. Tumor resection
is of prognostic value, and may be beneficial to attempt
maximal tumor resection [II, C]. Implantation of
chemotherapy-impregnated wafer (BCNU polymer) into the
resection cavity has shown only a marginal benefit in malignant
glioma versus radiotherapy alone [II, B].
Fractionated focal radiotherapy (60 Gy, 2 Gy · 30, or
equivalent doses/fractionations) is the standard treatment after
resection or biopsy [I, A]. Escalating doses beyond 60 Gy has
not been shown to be of value. In elderly patients or patients
with a low performance status, shorter hypofractionated
regimens (e.g. 40 Gy in 15 fractions) are commonly proposed
[II, B]. Radiotherapy (28 · 1.8 Gy, 50 Gy) in patients >70 years
of age was superior to best supportive care alone in
a randomized phase III trial [II, B].
Concomitant and adjuvant temozolomide chemotherapy has
been demonstrated to significantly improve median and 2-year
survival in a large randomized trial in glioblastoma [I, A].
Selecting patients likely to benefit from therapy on the basis of
MGMT gene promoter methylation has been suggested [II, B].
Adjuvant chemotherapy with procarbazine, lomustine and
vincristine (PCV regimen) has failed to improve survival in
prospective randomized studies [I, A]. Nevertheless, based on
a large meta-analysis [I, A] nitrosourea-based chemotherapy
may marginally improve survival in selected patients.
recurrent disease
Some benefit of chemotherapy has been shown for patients
with an adequate performance status who have not received
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prior adjuvant cytotoxic therapy. Anaplastic astrocytomas are
more likely than glioblastoma to respond to chemotherapy
[III, B]. For patients failing prior chemotherapy, there is no
established chemotherapy regimen available and patients
are best treated within investigational clinical protocols.
Single-agent nitrosourea therapy may improve tumor control
in some patients, while EGFR inhibition with erlotinib has
not demonstrated any measurable anti-tumor efficacy in a
randomized phase II trial [II, C].
Repeat surgery and implantation of chemotherapy-
impregnated polymers may prolong survival in selected patients
[II, B].
anaplastic oligodendroglioma
Oligodendroglioma carries a somewhat better prognosis. In
particular, the subgroup of patients with a deletion on
chromosome 1p and 19q seem to have a longer survival and
better response to chemotherapy compared with patients
without deletion. In patients with recurrent oligodendroglioma,
chemotherapy should be considered [II, B], while
(neo)adjuvant PCV chemotherapy [procarbazine, lomustine
(CCNU), vincristine] has failed to improve survival in patients
in addition to radiotherapy in newly diagnosed anaplastic
oligoastrocytoma and oligodendroglioma [I, B].
response evaluation
If response is evaluated, it should be done with MRI. Contrast
enhancement and presumed tumor progression on imaging 4–8
weeks after the end of radiotherapy may be an imaging artefact
(pseudoprogression) and should be re-evaluated 4 weeks later
with a second MRI.
Response to chemotherapy is evaluated according to the
WHO criteria, but should also include an assessment of
neurological function and corticosteroid use (Macdonald
criteria). The rate of patients alive and progression free at 6
months (PFS6mo) has been recognized as a valid endpoint and
also includes patients who benefit from therapy by disease
stabilization.
follow-up
Follow-up consists of a clinical evaluation with particular
attention to neurological function, seizures or seizure
equivalents and corticosteroid use. Patients should be tapered
off steroid use as early as possible. Venous thrombotic events
occur frequently in patients with unresected or recurrent
tumors.
Laboratory tests are not indicated unless the patient is
receiving chemotherapy (blood count), corticosteroids (glucose)
or antiepileptic drugs (blood count, liver function tests).
note
Levels of evidence [I–V] and grades of recommendation [A–D]
as used by the American Society of Clinical Oncology are
given in square brackets. Statements without grading were
considered justified standard clinical practice by the expert
authors and the ESMO faculty.
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